Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | AHR | P35869 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38659577 | 0.80 | KDR (0.37) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL20601780 | 0.77 | FLT3 (0.36) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL3782472 | 0.77 | KDR (0.35) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL1445148 | 0.77 | KDM4E (0.37) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL560319 | 0.77 | KDR (0.35) | KDRKDM4EALDH1A1GAAPKM | |
| SCHEMBL557273 | 0.77 | KDR (0.41) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL21591164 | 0.77 | FLT3 (0.40) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL10138747 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1GAAPKMFLT3 | |
| SCHEMBL20985905 | 0.74 | KDM4E (0.36) | KDRAHRKDM4EALDH1A1GAA | |
| SCHEMBL23089490 | 0.73 | KDR (0.33) | KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-3806853-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | ONCO3R THERAPEUTICS BV (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4559906-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-05-08 | — | — | US | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2408773-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3CD, PIK3CG | KDR 975/4885AHR 4540/4885KDM4E 2981/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDR 1607/4885AHR 327/4885KDM4E 190/4885 |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | KDR 4573/4885AHR 1544/4885KDM4E 3766/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | KDR 419/4885AHR 213/4885KDM4E 650/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | KDR 141/4885AHR 330/4885KDM4E 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.